000120030 001__ 120030
000120030 005__ 20240319081004.0
000120030 0247_ $$2doi$$a10.1080/21505594.2022.2119657
000120030 0248_ $$2sideral$$a130854
000120030 037__ $$aART-2022-130854
000120030 041__ $$aeng
000120030 100__ $$aAsai, Masanori
000120030 245__ $$aGalleria mellonella as an infection model for the virulent Mycobacterium tuberculosis H37Rv
000120030 260__ $$c2022
000120030 5060_ $$aAccess copy available to the general public$$fUnrestricted
000120030 5203_ $$aTuberculosis (TB), caused by Mycobacterium tuberculosis (MTB), is a leading cause of infectious disease mortality. Animal infection models have contributed substantially to our understanding of TB, yet their biological and non-biological limitations are a research bottleneck. There is a need for more ethically acceptable, economical, and reproducible TB infection models capable of mimicking key aspects of disease. Here, we demonstrate and present a basic description of how Galleria mellonella (the greater wax moth, Gm) larvae can be used as a low cost, rapid, and ethically more acceptable model for TB research. This is the first study to infect Gm with the fully virulent MTB H37Rv, the most widely used strain in research. Infection of Gm with MTB resulted in a symptomatic lethal infection, the virulence of which differed from both attenuated Mycobacterium bovis BCG and auxotrophic MTB strains. The Gm-MTB model can also be used for anti-TB drug screening, although CFU enumeration from Gm is necessary for confirmation of mycobacterial load reducing activity of the tested compound. Furthermore, comparative virulence of MTB isogenic mutants can be determined in Gm. However, comparison of mutant phenotypes in Gm against conventional models must consider the limitations of innate immunity. Our findings indicate that Gm will be a practical, valuable, and advantageous additional model to be used alongside existing models to advance tuberculosis research.
000120030 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000120030 590__ $$a5.2$$b2022
000120030 592__ $$a1.104$$b2022
000120030 591__ $$aIMMUNOLOGY$$b64 / 161 = 0.398$$c2022$$dQ2$$eT2
000120030 593__ $$aMicrobiology$$c2022$$dQ1
000120030 591__ $$aMICROBIOLOGY$$b38 / 135 = 0.281$$c2022$$dQ2$$eT1
000120030 593__ $$aInfectious Diseases$$c2022$$dQ1
000120030 591__ $$aINFECTIOUS DISEASES$$b29 / 96 = 0.302$$c2022$$dQ2$$eT1
000120030 593__ $$aParasitology$$c2022$$dQ1
000120030 593__ $$aMicrobiology (medical)$$c2022$$dQ1
000120030 593__ $$aImmunology$$c2022$$dQ2
000120030 594__ $$a7.3$$b2022
000120030 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000120030 700__ $$aLi, Yanwen
000120030 700__ $$aSpiropoulos, John
000120030 700__ $$aCooley, William
000120030 700__ $$aEverest, David J.
000120030 700__ $$aKendall, Sharon L.
000120030 700__ $$0(orcid)0000-0003-2993-5478$$aMartín, Carlos$$uUniversidad de Zaragoza
000120030 700__ $$aRobertson, Brian D.
000120030 700__ $$aLangford, Paul R.
000120030 700__ $$aNewton, Sandra M.
000120030 7102_ $$11011$$2630$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Microbiología
000120030 773__ $$g13, 1 (2022), 1543-1557$$pVIRULENCE$$tVirulence$$x2150-5594
000120030 8564_ $$s9569266$$uhttps://zaguan.unizar.es/record/120030/files/texto_completo.pdf$$yVersión publicada
000120030 8564_ $$s1145952$$uhttps://zaguan.unizar.es/record/120030/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000120030 909CO $$ooai:zaguan.unizar.es:120030$$particulos$$pdriver
000120030 951__ $$a2024-03-18-14:26:49
000120030 980__ $$aARTICLE